Inside the Mixed Signals of a U.S. Manufacturing Revival

Why It Matters

The divergence between announced investment and actual capacity affects capital allocation, supply‑chain resilience, and policy decisions for a sector critical to U.S. economic competitiveness.

Key Takeaways

• Advanced plant costs 57% above 10‑year average
• Only 33% of announced projects have started production
• Stall rate hit 70% in late 2024, now declining
• Top five states capture >50% of new projects
• Tariffs boost traditional output but hinder advanced manufacturing

Pulse Analysis

The latest data from Savills underscores a nuanced revival in U.S. manufacturing. While headline numbers tout a boom in new plant announcements—particularly for high‑tech assets like EV‑battery and semiconductor fabs—the reality on the ground tells a different story. Only about a third of projects disclosed over the past five years have moved beyond the planning stage, and a historic stall rate of 70% in late 2024 highlighted the fragility of these pipelines. This gap between intent and execution signals that investors and developers must scrutinize project viability beyond the initial press release.

Policy and cost dynamics are central to the mixed signals. Government incentives, proximity to customers, and a skilled labor pool remain the top drivers of reshoring, while tariffs have slipped to the tenth most‑cited factor despite a recent uptick in relevance. The One Big Beautiful Bill Act’s 100% rapid depreciation provision and heightened defense spending have spurred activity in aerospace, defense, and data‑center infrastructure, yet the same incentives have constrained clean‑tech supply chains. Understanding how these levers interact helps firms navigate a landscape where traditional manufacturing benefits from protective measures, but advanced sectors face higher input costs and supply‑chain complexities.

Sectoral shifts and regional clustering further shape the outlook. Aerospace and defense now account for 40% of new announcements, buoyed by a 300% surge in venture‑capital funding, while AI‑driven energy infrastructure projects rank second. Life‑science manufacturing, especially for GLP‑1 drugs, is emerging as a niche growth area. Over half of the announced projects are concentrated in five states—North Carolina, Texas, Arizona, Tennessee and South Carolina—thanks to favorable land prices, labor availability, and pro‑business policies. This concentration suggests that future manufacturing momentum will likely be driven by a handful of hubs that can align cost, talent, and policy incentives effectively.